… We performed a retrospective population-based cohort study to determine the incidence of
bleeding in patients with atrial fibrillation (AF) beginning dabigatran, rivaroxaban or warfarin. …

… Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial
fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013;61:2264-73. doi:…

… The aim of this study was to assess the association between the use … dabigatran, rivaroxaban,
and apixaban and the risk of stroke or SE and bleeding in a nationwide cohort of patients …

… on patients receiving standard dosages of apixaban, dabigatran, and rivaroxaban, because
… These two classifications represented primary and secondary prevention treatment groups, …

… This study used a similar design to ours and saw more events, but it included only … by
dabigatran dose (24). Finally, outside of our study, separate analyses of dabigatran versus warfarin …

… In our nationwide cohort study of 31 522 OAC-naïve AF patients initiating NOAC treatment,
the associated stroke risks were similar in comparison with standard dose NOACs or in …

… nationwide population-based cohort study showed that NOACs were superior to warfarin for
the secondary prevention … standard-dose NOAC users (dabigatran 150 mg bid, rivaroxaban …

… Also, we found that among patients with high stroke and bleeding risks, dabigatran was the
only NOAC associated with the persistence of a significant low risk of intracranial bleeding. …

… with atrial fibrillation with more than 2 stroke risk factors, with … dabigatran or apixaban including
few patients with 1 stroke risk … on stroke prevention for patients with atrial fibrillation with 1 …

… atrial fibrillation (AF) patients with ≥1 stroke risk factors. We describe the effectiveness and
safety of dabigatran … -interventional studies based on, for example, claims data or nationwide …